Earnings & Reporting

Radisson Hotel Group and SMHCC ink a deal for three new hotels, a strategic move to dominate the MICE market and capitalize on the Philippines' resurgence.

Fairholme's year-end dividends are more than just income. We dissect the funds' high-risk, non-diversified strategy and what it means for investors.

TPG RE Finance Trust declared a steady $0.24 dividend. We analyze if this signals portfolio resilience or a strategic play in a volatile market.

Valmet’s oversubscribed €375M Schuldschein loan isn't just a funding win. It's a strategic pivot showcasing the rising power of private debt markets.

A new partnership combines 3D depth with panoramic visuals, creating an unparalleled movie experience. But is it enough to win the premium cinema war?

Dynex's routine dividend declaration reveals a complex strategy of risk management and capital allocation, offering a masterclass in navigating mREIT turbulence.

New journalism awards tackle AI's risks and Indigenous health gaps, revealing how media innovation aims to build a healthier, more equitable Canada.

Nusano won a "Best Company" award, but the real story is how its culture is a strategic asset powering its mission to disrupt the critical isotope market.

KBRA rates a $328M mortgage trust with significant 'non-prime' loans, signaling a boom in a market segment that balances risk with investor demand.

With a new CEO, Menagerie Cellars is doubling down on its blend of luxury wine and conservation. Can this purpose-driven model scale in a tough market?

Lion Group's $8M Bitcoin purchase highlights a growing corporate trend, but a plunging stock price reveals the immense risks of digital asset treasuries.

A new inflation metric from Numerator does more than track prices; it signals a new era where private firms provide strategic economic intelligence.

Xtant Medical's new nanOss Strata bone graft isn't just an update; it's a strategic move to disrupt the orthobiologics market. Here's why it matters.

Polyrizon's novel hydrogel shows it can stick to nasal tissue longer without slowing drug delivery, a key innovation in the fight against opioid overdose.

Beyond its first-ever dividend, Covalon's true story is one of clinical innovation driving record sales, navigating market shifts, and funding global growth.

Target's holiday push is more than a sale; it's a high-stakes play using AI, exclusive drops, and logistics to win the final days of retail's biggest battle.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

South Korean tobacco giant KT&G just earned a flawless 'AAA' ESG rating, a first for its industry. What does this mean for investors and sustainability?

Shareholders approve Emeren's $102M deal to go private, a maneuver to accelerate growth in the booming solar and battery storage markets. What's next?

NREF's massive capital raise signals strong investor confidence. We dive into what this bold move reveals about the market and income-seeking investors.